2007
Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma
Huang GS, Chiu LG, Gebb JS, Gunter MJ, Sukumvanich P, Goldberg GL, Einstein MH. Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma. Gynecologic Oncology 2007, 107: 513-517. PMID: 17935762, PMCID: PMC2696225, DOI: 10.1016/j.ygyno.2007.08.060.Peer-Reviewed Original ResearchConceptsDeep myometrial invasionCA125 elevationExtrauterine diseasePrognostic factorsUterine carcinosarcomaPreoperative CA125CA125 levelsCA125 measurementMyometrial invasionPoor survivalExact testCox proportional hazards modelClinicopathologic prognostic factorsEstrogen receptor positivityIndependent prognostic factorManagement of patientsUnivariate survival analysisUseful serum markerPearson's chi-square testProportional hazards modelFisher's exact testChi-square testSerous histologyConsecutive patientsReceptor positivity
2006
Survival and toxicity differences between 5‐day and weekly cisplatin in patients with locally advanced cervical cancer
Einstein MH, Novetsky AP, Garg M, Hailpern SM, Huang GS, Glueck A, Fields AL, Kalnicki S, Goldberg GL. Survival and toxicity differences between 5‐day and weekly cisplatin in patients with locally advanced cervical cancer. Cancer 2006, 109: 48-53. PMID: 17123270, DOI: 10.1002/cncr.22369.Peer-Reviewed Original ResearchConceptsProgression-free survivalAdvanced cervical cancerCervical cancerWeekly groupWeekly CDDPAdvanced stage cervical cancerAdvanced-stage patientsCompletion of treatmentTimes higher riskExternal beam radiotherapyAcute toxicitySignificant demographic differencesOutpatient regimenWeekly cisplatinWeekly regimenConsecutive patientsTreatment failureSingle institutionDay concomitantBeam radiotherapyHigh riskRate brachytherapy treatmentPatientsRegimenRadiotherapy